Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Design Therapeutics (DSGN) Enterprise Value (2020 - 2026)

Design Therapeutics' Enterprise Value history spans 2 years, with the latest figure at -$384.1 million for Q4 2021.

  • On a quarterly basis, Enterprise Value fell 15731.16% to -$384.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was -$384.1 million, a 15731.16% decrease, with the full-year FY2021 number at -$384.1 million, down 15731.16% from a year prior.
  • Enterprise Value hit -$384.1 million in Q4 2021 for Design Therapeutics, down from -$357.8 million in the prior quarter.
  • Over the last five years, Enterprise Value for DSGN hit a ceiling of -$2.4 million in Q4 2020 and a floor of -$402.8 million in Q2 2021.